Clinical Trials · NCT01048086
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- University of Iowa
- Enrollment
- 0
- Start date
- Jun 2009
- Locations
- 1 site, United States
- Primary endpoint
- Evaluate tumor response to 90Y-DOTA-tyr3-Octreotide alone and in combination with 13-cis retinoic acid for the treatment of children and young adults with recurrent, somatostatin-receptor positive tumors